What is the recommended approach to initiating and monitoring testosterone replacement therapy for symptomatic hypogonadism?

Testosterone Replacement Therapy: Initiation and Monitoring

Diagnosis and Initiation

Initiate testosterone replacement therapy only when total testosterone is below 300 ng/dL on two separate early morning measurements AND the patient has symptoms of hypogonadism. 1

Diagnostic Requirements

• Measure total testosterone twice on separate occasions, both in early morning (fasting), using the same laboratory and method 1
• Confirm symptoms such as reduced libido, erectile dysfunction, decreased energy, fatigue, reduced muscle mass, or depressed mood 1
• Measure luteinizing hormone (LH) to distinguish primary from secondary hypogonadism 1
• Do not rely on questionnaires for diagnosis—they lack specificity and should not replace laboratory testing 1

Baseline Evaluation Before Starting Therapy

Before initiating testosterone therapy, perform the following baseline assessments: 1

• Prostate evaluation:

  • Digital rectal examination 1
  • PSA measurement 1
  • Perform prostate biopsy if PSA >4.0 ng/mL or abnormal digital rectal examination 1

• Hematologic assessment:

  • Hematocrit or hemoglobin 1

• Clinical history:

  • Voiding symptoms (use standardized questionnaire) 1
  • Sleep apnea history 1

Absolute Contraindications

Do not initiate testosterone therapy in men with: 1, 2, 3

• Active breast cancer 1
• Untreated prostate cancer 1, 2
• Severe heart failure or recent cardiovascular event (within 4 months) 4, 2
• Hematocrit >48-50% 2
• Men actively seeking fertility (use gonadotropins instead) 1, 2

---

Monitoring Protocol

Initial Follow-Up

Assess efficacy and adjust dosage at 1-2 months after initiation. 1

Ongoing Monitoring Schedule

Monitor every 3-6 months during the first year, then annually thereafter. 1

Parameters to Monitor at Each Visit

At every monitoring visit, assess the following: 1

• Symptom response (sexual function, energy, mood) 1
• Testosterone level (ensure therapeutic range achieved) 1
• Hematocrit or hemoglobin (watch for erythrocytosis) 1
• PSA level 1
• Digital rectal examination 1
• Urinary symptoms (worsening LUTS) 1
• Sleep apnea (new onset or exacerbation) 1
• Gynecomastia 1

---

PSA Monitoring and Prostate Biopsy Triggers

The most conservative approach for PSA monitoring during testosterone therapy is: 1

• Perform prostate biopsy if PSA rises ≥1.0 ng/mL in any 12-month period 1
• If PSA increases by 0.7-0.9 ng/mL in one year, repeat PSA in 3-6 months and perform biopsy if any further increase 1
• Perform biopsy if PSA exceeds 4.0 ng/mL 1
• Perform biopsy if digital rectal examination shows new nodule, asymmetry, or increased firmness 1

This approach is more stringent than other published recommendations but is justified by the concern of unmasking previously occult prostate cancer during the first year of therapy. 1

---

Treatment Selection

Prefer transdermal testosterone (gel or patch) for initiation, especially in older men. 1, 4, 2

• Transdermal formulations allow for easier dose adjustment and rapid discontinuation if adverse effects occur 2
• Injectable testosterone may be considered subsequently for convenience and cost 1
• Avoid oral testosterone preparations due to hepatotoxicity risk (except testosterone undecanoate, not available in the U.S.) 1

---

Special Considerations

Erythrocytosis Risk

Erythrocytosis is the most common adverse effect requiring monitoring: 1

• Risk varies by formulation: 3-18% with transdermal, up to 44% with injections 1
• Discontinue or reduce dose if hematocrit exceeds 54% 1

Cardiovascular Safety

Recent evidence from the TRAVERSE trial demonstrates that testosterone therapy does not increase cardiovascular risk in appropriately selected patients. 5, 6

• Earlier concerns about cardiovascular events have not been substantiated by high-quality randomized trials 1, 5, 6
• However, avoid testosterone in men with recent myocardial infarction or stroke (within 4 months) 4, 2

Fertility Preservation

For men with secondary hypogonadism who desire fertility, use gonadotropin therapy (hCG with or without FSH) instead of testosterone. 1, 2

• Testosterone therapy suppresses spermatogenesis and is contraindicated in men seeking fertility 1, 2

---

Common Pitfalls to Avoid

• Do not start testosterone without confirming low levels on two separate morning measurements 1
• Do not treat based on symptoms alone—many symptoms are nonspecific 1
• Do not skip baseline prostate evaluation—this is essential for safety monitoring 1
• Do not ignore hematocrit monitoring—erythrocytosis is common and potentially dangerous 1
• Do not use testosterone in eugonadal men—there is no benefit and potential harm 1